CluePoints Taps Tech Veteran to Lead People Strategy Amid AI-Fueled Growth

KING OF PRUSSIA, Pa. – January 13, 2026 – In a move that underscores the critical link between human capital and technological innovation, AI-driven clinical trial software provider CluePoints has appointed Sinead Godkin as its new Chief People Officer (CPO). The appointment comes as the company navigates a period of explosive growth, positioning itself to further dominate the rapidly expanding market for Risk-Based Quality Management (RBQM) in clinical research.

Godkin, a seasoned executive with a deep background in scaling global technology organizations, will lead the company’s people strategy. Her arrival is a clear signal that as CluePoints’ AI and machine learning algorithms become more sophisticated, the firm is making an equally significant investment in the human architecture required to sustain its momentum.

The Human Engine Behind Hyper-Growth

CluePoints is on a steep upward trajectory. The company, which provides software to determine the quality and integrity of clinical trial data, added more than 100 new employees in 2025, a significant expansion of its workforce which now numbers over 300 across two continents. This hiring surge follows a landmark 2024 investment when private equity firm EQT acquired a majority stake to fuel the company's next stage of growth and product development. With estimated annual revenues climbing towards the $50-$100 million range, the firm's expansion is palpable.

This rapid scaling brings immense opportunity but also significant challenges in preserving the culture and operational agility that fueled its initial success. Andy Cooper, CEO at CluePoints, highlighted this balance in his announcement. "People are our most important asset at CluePoints," he commented. "As we continue to grow, it is vital we maintain the same culture of care and development that CluePoints is built on."

Bringing in a CPO of Godkin’s caliber is a strategic play to ensure the company's internal structures don't just survive this growth but enable it. The challenge for many high-growth tech firms is that their internal processes and cultural frameworks can lag behind their product innovation and market expansion, leading to operational friction, employee burnout, and a dilution of core values. Godkin’s primary task is to build a people organization that is as scalable and sophisticated as the company's technology.

A Veteran's Blueprint for Scaling Niche Tech

Sinead Godkin’s resume reads like a playbook for managing the complexities of evolving tech giants. Her experience includes senior leadership roles at Veritas Technologies and Symantec, companies that navigated massive corporate transformations, including splits and acquisitions. More recently, as CPO at the digital trust provider DigiCert, she was a key executive supporting the scale-up of a private equity-owned organization through periods of accelerated growth.

This background provides her with a rare combination of international experience and commercial insight tailored for CluePoints' current situation. She has direct experience in building global workforce strategies within complex, multinational environments and transforming people operations during periods of intense change. Her expertise will be critical in creating the leadership and development frameworks needed to manage a larger, more geographically dispersed team.

"CluePoints is at an exciting point in its history, scaling globally, evolving rapidly, and continuing to push the boundaries of how technology can improve clinical research," Godkin stated. Her focus, she added, will be to "build on the strong culture already in place and to help create the leadership, development, and people frameworks that enable both individuals and the organization to thrive as we scale."

AI Inside and Out: Transforming Trials and a Company

CluePoints has cemented its reputation by applying cutting-edge AI and machine learning to the high-stakes world of clinical trials. The global RBQM market, which its solutions target, is projected to reach $2.5 billion by 2033, driven by regulatory demand for more efficient and reliable trial oversight. With 96% of clinical trials in 2024 incorporating at least one RBQM component, CluePoints is at the center of an industry-wide paradigm shift.

Now, the company is turning that innovative lens inward. A key part of Godkin's mandate is to explore how emerging technologies, including AI-enabled tools, can create more effective and scalable ways of working internally. This dual application of AI—both as an external product and an internal optimization tool—reflects a sophisticated, forward-thinking strategy.

This initiative aligns with a powerful trend in human resources. According to industry analysts at Gartner, the percentage of HR leaders planning or deploying generative AI solutions skyrocketed from 19% in mid-2023 to over 60% by early 2025. AI is being used to screen resumes, create personalized employee learning paths, analyze engagement data, and automate routine HR tasks, freeing up people teams to focus on more strategic work. By tasking its new CPO with this exploration, CluePoints is aiming to match its external innovation with internal efficiency, ensuring growth is supported by clarity and opportunity for its employees.

Charting a Course in a Competitive Landscape

Godkin’s appointment is also a competitive maneuver in the fierce clinical technology space. CluePoints competes with major players like IQVIA, Ennov, and Medrio, all vying for a share of the clinical trial technology market, which is expected to exceed $110 billion by 2034. CluePoints differentiates itself through its deep focus on advanced statistics and machine learning, a specialty that has earned it an extended partnership with the U.S. Food and Drug Administration (FDA) to explore data-driven trial oversight.

To maintain this innovative edge, the company must continue to attract and retain elite talent in data science, software engineering, and clinical research. A world-class people strategy is not a support function but a core competitive advantage. By professionalizing its HR function under a leader experienced in hyper-growth, CluePoints is building the organizational resilience needed to out-innovate competitors and respond to the evolving demands of the pharmaceutical and biotech industries.

As CluePoints continues to develop algorithms that bring new levels of clarity to complex clinical data, the parallel development of its human systems will be just as crucial. The success of its next chapter will be measured not only by the power of its software but by the strength, engagement, and adaptability of the global team that builds it.